Skip to content

Journal · Molecular diagnostics · Updated 21 November 2026

Molecular Diagnosis & Therapy

Read Molecular Diagnosis & Therapy articles on DeepDyve. No university library needed.

Molecular Diagnosis & Therapy publishes reviews and research on molecular testing, biomarkers and precision medicine, from RNA sequencing and tumor mutation testing to new molecular targets for treatment. Springer Nature publishes it. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Springer Nature.

Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.

Personal plans aren’t for business use. Reading for work? See Enterprise.

Cover of Molecular Diagnosis & Therapy
Journal cover

Molecular Diagnosis & Therapy at a glance

Full title
Molecular Diagnosis & Therapy
Abbreviation (NLM)
Mol Diagn Ther
Publisher
Springer Nature
Print ISSN
1177-1062
Online ISSN (eISSN)
1179-2000
Subjects
Clinical Laboratory Techniques, Molecular Biology, Pharmacology
Access model
Hybrid (37% free to read in 2026)

Ways to access Molecular Diagnosis & Therapy

37% of the articles Molecular Diagnosis & Therapy published from January 1 to November 19, 2026 are open access and free to read. For the rest, look for the authors’ manuscript, check a library, or read them on DeepDyve.

  1. Open access articles. 37% of Molecular Diagnosis & Therapy articles published from January 1 to November 19, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
  2. The authors’ accepted manuscript. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication.
  3. Ask the authors. Authors can also share a free, read-only link to their published article through Springer Nature’s SharedIt, so it’s worth asking the authors directly.
  4. NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
  5. A library. Your university, hospital or public library may subscribe to Molecular Diagnosis & Therapy. Check its journal list and whether it offers remote access.
  6. DeepDyve. Read Molecular Diagnosis & Therapy articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.

Sources: Springer Nature self-archiving policy; NIH Public Access Policy; open access share from Crossref license data.

Impact factor and metrics

Molecular Diagnosis & Therapy’s 2025 Journal Impact Factor is 5.8, and its 5-year Impact Factor is 5.2.

5.8

Journal Impact Factor (2025)

5.2

5-year Impact Factor (2025)

7 days

Median time to first decision

Source: journal metrics on the Molecular Diagnosis & Therapy homepage (Springer Nature), checked November 21, 2026. Impact Factor from Clarivate Journal Citation Reports.

Recent Molecular Diagnosis & Therapy research worth reading

Published January to March 2026. Summaries describe what the authors report.

  1. Open accessRNA sequencing · Cytopathology

    Pre-analytical Best Practices for RNA Sequencing from Small Biopsies and Cytologic Specimens

    A working group of National Cancer Institute grantees and researchers reviews pre-analytical best practices for RNA sequencing of small biopsies and cytology specimens, including ways to assess specimen adequacy, maximize tumor content and limit RNA degradation during handling.

    Sura et al. · Molecular Diagnosis & Therapy, published online March 14, 2026 · DOI 10.1007/s40291-026-00837-6

  2. LitStreamSarcopenia · Neuromuscular junction

    Neuromuscular Junction as a Molecular Target in Sarcopenia: Mechanisms, Therapeutic Strategies, and Future Directions

    The authors review evidence that degeneration of the neuromuscular junction is an early event in sarcopenia, and discuss therapies aimed at preserving synaptic integrity along with biomarkers such as circulating c-terminal agrin fragment-22 (CAF22).

    Qaisar et al. · Molecular Diagnosis & Therapy, published online January 31, 2026 · DOI 10.1007/s40291-026-00833-w

  3. LitStreamOlfactory receptors · Precision medicine

    The Emerging Role of Olfactory Receptors: From Genomics to Precision Medicine

    The authors review evidence that olfactory receptors expressed outside the nose, in tissues such as the gut, brain, skin and tumors, act as signaling molecules, and discuss their potential as biomarkers and therapeutic targets in precision medicine.

    Dubey et al. · Molecular Diagnosis & Therapy, published online January 30, 2026 · DOI 10.1007/s40291-026-00832-x

  4. LitStreamGene therapy · Wiskott-Aldrich syndrome

    Etuvetidigene Autotemcel: First Approval

    Blair summarizes the development milestones of etuvetidigene autotemcel, an autologous haematopoietic stem cell-based gene therapy for Wiskott-Aldrich syndrome that was approved in the USA in December 2025 and in the EU in January 2026.

    Blair · Molecular Diagnosis & Therapy, published online March 25, 2026 · DOI 10.1007/s40291-026-00843-8

  5. LitStreamGastrointestinal cancer · Antibody-drug conjugates

    TROP2-Targeted Therapeutics in Development to Treat Gastrointestinal Tumors

    Rogers reviews progress on TROP2-targeting therapies in gastrointestinal cancers, noting that early phase 1/2 data show some activity in colorectal and gastroesophageal cancer and that studies are underway in colorectal, pancreatic, biliary tract and gastroesophageal cancers.

    Rogers · Molecular Diagnosis & Therapy, published online February 11, 2026 · DOI 10.1007/s40291-026-00835-8

See every Molecular Diagnosis & Therapy article on DeepDyve

Questions about Molecular Diagnosis & Therapy

How can I read Molecular Diagnosis & Therapy articles without a subscription?

37% of Molecular Diagnosis & Therapy articles published from January 1 to November 19, 2026 are open access and free to read. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication. Your library may also subscribe. DeepDyve lets you read Molecular Diagnosis & Therapy articles online for $59 a month or $499 a year after a free first month.

What is the abbreviation for Molecular Diagnosis & Therapy?

Molecular Diagnosis & Therapy’s NLM (PubMed) abbreviation is Mol Diagn Ther.

What is the ISSN of Molecular Diagnosis & Therapy?

The print ISSN is 1177-1062 and the online ISSN is 1179-2000.

What is the impact factor of Molecular Diagnosis & Therapy?

Molecular Diagnosis & Therapy’s Journal Impact Factor is 5.8 (2025), and its 5-year Impact Factor is 5.2, according to Springer Nature’s published metrics.

Is Molecular Diagnosis & Therapy open access?

Molecular Diagnosis & Therapy is a hybrid journal: most articles are published under the subscription model, and authors can choose to publish open access. From January 1 to November 19, 2026, 22 of 59 Molecular Diagnosis & Therapy articles (37%) carry a Creative Commons license, per Crossref.

Molecular Diagnosis & Therapy articles on DeepDyve are licensed from Springer Nature. Journal facts as of 21 November 2026.

Start reading Molecular Diagnosis & Therapy today

One month free, then less than $2 a day. Molecular Diagnosis & Therapy, plus millions of articles from thousands of journals.

Start free month

Like this: